Advances in CRISPR-Cas
The CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR associated nucleases) system was originally discovered to be an acquired immune response mechanism used by archaea and bacteria. It has since been adopted for use as a tool in the genetic engineering of higher organisms. Designing an appropriate gRNA is an important element of genome editing with the CRISPR/Cas system. A gRNA can and at times does have unintended interactions ("off-targets") with other locations of the genome of interest. For a given candidate gRNA, these tools report its list of potential off-targets in the genome thereby allowing the designer to evaluate its suitability prior to embarking on any experiments.
In the present book, ten typical literatures about CRISPR-Cas published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on CRISPR-Cas. We hope this book can demonstrate advances in CRISPR-Cas as well as give references to the researchers, students and other related people.
Sample Chapter(s)
Preface (178 KB)
Components of the Book:
  • Chapter 1
    Frontiers in antibiotic resistance: emerging alternatives, key challenges, and the transformative role of CRISPR-Cas
  • Chapter 2
    Anoxia activates CRISPR–Cas immunity in the mouse intestine
  • Chapter 3
    CRISPR/Cas9 as a Mutagenic Factor
  • Chapter 4
    CRISPR/Cas system-mediated gene editing for disease resistance in food crops: current status and future directions
  • Chapter 5
    An updated evolutionary classification of CRISPR–Cas systems including rare variants
  • Chapter 6
    Phage induction of Staphylococcus aureus pathogenicity islands promotes the CRISPR-Cas adaptive immune response
  • Chapter 7
    CRISPR/Cas strategies to enhance CAR T-cell function and persistence via metabolic reprogramming
  • Chapter 8
    CRISPR/Cas as a tool to overcome drug resistance in cancer: From challenge to opportunity
  • Chapter 9
    Technical constraints in translating paper-based CRISPR/Cas assays to wearable formats
  • Chapter 10
    CRISPR/Cas-Based Nanobiosensor Using Plasmonic Nanomaterials to Detect Disease Biomarkers
Readership: Students, academics, teachers and other people attending or interested in integrated CRISPR-Cas.
Janne Ruokolainen
Department of Applied Physics, School of Science, Aalto University, Espoo, Finland

Ian W. Campbell
Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA; Department of Microbiology, Harvard Medical School, Boston, MA, USA

Han Altae-Tran
Institute for Protein Design, University of Washington, Seattle, WA, USA

and more...
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top